MedTrace Logo

The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT

NCT05202587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 386

Last updated 2023-02-15

No results posted yet for this study

Summary

This multi-center study will enroll Adult subjects diagnosed with neo-vascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment. the subject study duration for this study is one day (2-3 hours). Each study site will have two NVHO devices and one Cirrus 5000 and the patients will be scand on the two NVHO devices and one Cirrus device as a part of the study flow. At the Study Visit, fluid must be present in approximately 280 study eyes and fluid must be absent from 20 study eyes. Each subject will only have one study eye. The fluid status will be determined by the investigator while reviewing an acceptable screening Cirrus OCT volume scan.

Conditions

  • Neovascular Age-related Macular Degeneration

Sponsors & Collaborators

  • Notal Vision Inc.

    lead INDUSTRY

Principal Investigators

  • Gidi Benyamini · Notal vision Druyanov 5, Tel Aviv

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2023-01-12
Completion
2023-01-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202587 on ClinicalTrials.gov